SCHEMBL29499587

SCHEMBL29499587

Cc1cc(OS(=O)(=O)C(F)(F)F)cc(C)c1C(N)=O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 3/20 0.38
CXCR2 P25025 2/20 0.38
HSD11B1 P28845 1/20 0.37
CXCR1 P25024 1/20 0.37
CA1 P00915 1/20 0.34
CA2 P00918 1/20 0.34
HTR1A P08908 1/20 0.33
HTR1D P28221 1/20 0.33
HTR1B P28222 1/20 0.33
CYP3A4 P08684 2/20 0.33
HPGD P15428 2/20 0.33
KMT2A Q03164 2/20 0.33
MEN1 O00255 1/20 0.33
ALDH1A1 P00352 1/20 0.33
ALOX15 P16050 1/20 0.33
MAPK1 P28482 1/20 0.33
HSD17B10 Q99714 1/20 0.33
ADORA2A P29274 1/20 0.32
ADORA1 P30542 1/20 0.32
KDM4E B2RXH2 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3829429 0.86 CYP3A4 (0.41) POLBCXCR2HSD11B1CXCR1CA1
SCHEMBL2380488 0.85 HSD11B1 (0.44) POLBCXCR2HSD11B1CXCR1CA1
SCHEMBL10073218 0.82 CYP3A4 (0.49) POLBCXCR2HSD11B1CXCR1CA1
SCHEMBL3765038 0.80 CYP2C9 (0.37) POLBCXCR2HSD11B1CXCR1CA1
SCHEMBL10073222 0.78 CXCR2 (0.40) CXCR2HSD11B1CXCR1CA1CA2
SCHEMBL28162652 0.77 CXCR2 (0.36) POLBCXCR2HSD11B1CXCR1CYP3A4
SCHEMBL3203223 0.75 TSHR (0.36) CXCR2HSD11B1CXCR1CA1CA2
SCHEMBL1505411 0.75 ALDH1A1 (0.39) CXCR2HSD11B1CXCR1CA1CA2
SCHEMBL1252245 0.74 CXCR2 (0.34) CXCR2HSD11B1CXCR1CA1CA2
SCHEMBL926505 0.73 CA2 (0.41) CXCR2HSD11B1CXCR1CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250042870-A1 DP ANTAGONIST ONO PHARMACEUTICAL CO., LTD. (JP) 2025-02-06 US disclosed
EP-3854781-B1 DP ANTAGONISTS ONO PHARMACEUTICAL CO (JP) 2024-05-22 EP disclosed
US-20220204468-A1 DP ANTAGONIST ONO PHARMACEUTICAL CO., LTD. (JP) 2022-06-30 US disclosed
US-11319296-B2 DP antagonist ONO PHARMACEUTICAL CO., LTD. (JP) 2022-05-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220204468-A1 DP ANTAGONIST OPRL1, CNR1, NPSR1 POLB 4038/4885CXCR2 1315/4885HSD11B1 2075/4885
US-11319296-B2 DP antagonist OPRL1, CNR1, NPSR1 POLB 4038/4885CXCR2 1315/4885HSD11B1 2075/4885
US-20250042870-A1 DP ANTAGONIST OPRL1, CNR1, NPSR1 POLB 4038/4885CXCR2 1315/4885HSD11B1 2075/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.